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Effects of Acute and Chronic Inflammation on B-Cell
Development and Differentiation
Derek Cain1, Motonari Kondo1, Huaiyong Chen1 and Garnett Kelsoe1
Recently, our understanding of hematopoiesis and the development of the immune system has fundamentally
changed, leading to significant discoveries with important clinical relevance. Hematopoiesis, once described in
terms of irreversible and discrete developmental branch points, is now understood to exist as a collection of
alternative developmental pathways capable of generating functionally identical progeny. Developmental
commitment to a particular blood-cell lineage is gradually acquired and reflects both cell intrinsic and extrinsic
signals. Chief among the extrinsic factors are the environmental cues of hematopoietic microenvironments that
comprise specific ‘‘developmental niches’’ that support hematopoietic stem and progenitor cells. Most of this
new understanding comes from the study of normal, steady-state hematopoiesis, but there is ample reason to
expect that special developmental and/or differentiative mechanisms operate in response to inflammation. For
example, both stem and progenitor cells are now known to express Toll-like receptors that can influence
hematopoietic cell fates in response to microbial products. Likewise, proinflammatory cytokines mobilize
hematopoietic stem cells to peripheral tissues. In this Perspective, we review inflammation’s effects on central
and extramedullary B lymphopoiesis and discuss the potential consequences of peripheral B-cell development
in the context of systemic autoimmune diseases.
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INTRODUCTION
B lymphocytes and antibodies are
crucial components of both innate and
adaptive immunity and provide for the
specific removal of pathogens and/or
their toxins. Indeed, the generation of
the memory B-cell compartments and
long-lived serum antibody provide the
basis for protective immunity elicited
by the great majority of contemporary
vaccines. B cells and their development
in the primary lymphoid tissues have
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Editor’s Note
In 1621 Fabricius ab Aquapendente described a sac-like
structure over the terminal gut in birds, known ever since as
the bursa of Fabricius (Ribatti et al., 2006). In 1954 Glick
and Chang found that immunized chickens in which the
bursa of Fabricius was removed early in development did
not develop antibodies, establishing this structure as critical
to antibody development (Ribatti et al., 2006). These
observations were followed by the work of Cooper and
Good, who suggested a functional division of immune cells,
with bursal (B) cells responsible for antibody production and
thymus (T) cells responsible for delayed-type hypersensitivity
(Cooper et al., 1965). Over the ensuing decades B cells have
been found to play a critical role in antibody formation, T
cell function and immune regulation (LeBien and Tedder,
2008). Recent development of the monoclonal antibody
rituximab, which is directed against a subset of B cells, has
resulted in a heightened interest in B cells as a target for the
treatment of autoimmune disease. In this issue Cain and
colleagues report on the role of acute and chronic
inflammation in B cell development, Manjarrez-Ordun˜o et
al focus on the role of B cells in the development of
immunological tolerance, and Nagel et al provide insight
into the potential for B-cell directed therapy of inflammatory
mediated skin diseases. In one of the first reviews of the
roles of T and B lymphocytes, Martin Raff wrote that
‘‘yinsight into the functioning of the immune systemy has
paved the way for rational attempts to manipulate selec-
tively the different cell typesy for the benefit of patientsy’’
(1973). These Perspectives outline advances towards the
fulfillment of Raff’s prediction.
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been the focus of intense study at the
molecular and cellular level over the
past several decades (for reviews, see
Hardy and Hayakawa, 2001; Defrance
et al., 2002). These investigations have
sharpened our understanding of how B-
cell antigen receptors are generated and
function and the role of B lymphocytes
in the organization and distribution of
secondary (Gonzalez et al., 1998) and
tertiary (Lorenz et al., 2003) lymphoid
tissues. Similarly, over the past 15 years
our knowledge of antigen-driven B-cell
differentiation and especially the germ-
inal center reaction has grown expo-
nentially leading to a basic
understanding of just how the humoral
immune response achieves its specifi-
city and affinity (Berek, 1993; Kelsoe,
1996; Bachmann, 1998).
Despite this hard-won, new knowl-
edge, immunologists have held tightly
to a classic notion that divides B-cell
development and differentiation into
distinct phases that are antigen inde-
pendent or dependent. Simply put,
antigens are generally not thought to
affect in any significant way the early
phases of B-cell development and
maturation in the bone marrow (BM;
Defrance et al., 2002). This classic
view places the earliest interaction
between B cells and exogenous antigen
in the spleen or other peripheral sites
where expansions or contractions of
B-cell populations are induced. This
view also implies that the tempo of B
lymphopoiesis does not respond to
external cues as does erythropoiesis
(Mide et al., 2001) and granulopoiesis
(Basu et al., 2000; Hirai et al., 2006).
However, recent studies indicate that
this view may no longer be tenable and
that infection, and even sterile inflam-
mation, control the site and rate of B
lymphopoiesis (Ueda et al., 2004,
2005). In this review, we shall provide
a concise overview of B-cell develop-
ment and differentiation in the BM and
periphery with a focus on the impact
that acute and chronic inflammation
has on these processes.
The process of B lymphopoiesis can
be divided roughly into four temporal
and spatial phases: early development
in the BM; maturation of immature/
transitional B cells during their transit
to the periphery; entry into the mature
B-cell compartments; and antigen-
dependent differentiation into anti-
body-secreting cells and/or memory B
cells (Hardy and Hayakawa, 2001;
Carsetti et al., 2004).
During their early development in
the BM, distinct stages of B-cell devel-
opment can be characterized by the
rearrangement status of immunoglobu-
lin genes (Hartley et al., 1991; Meffre
et al., 2000; Hardy and Hayakawa,
2001). Commitment to the B lineage
occurs before the initial rearrange-
ments of immunoglobulin gene seg-
ments that are necessary to construct a
functional B-cell antigen receptor
(BCR; Hardy et al., 1991; Allman
et al., 1999) and is identified as the
pre-pro-B-cell compartment (Hardy
et al., 1991). These earliest committed
progenitors express low levels of the
RAG1/2 recombinase (Schatz et al.,
1989; Oettinger et al., 1990), but have
immunoglobulin gene loci in an un-
rearranged, germline configuration
(Hardy et al., 1991). Subsequently,
pro-B cells highly express RAG1/2
(Hardy et al., 1991; Li et al., 1993)
and initiate DH-to-JH rearrangements
on both Igh alleles (Alt et al., 1984;
Ehlich et al., 1994). After DHJH rear-
rangement, VH-DHJH recombination
follows, but this event does not occur
simultaneously at both alleles (Alt
et al., 1984). Initial VHDHJH rearrange-
ments that are out-of-frame and
therefore, nonfunctional, can be com-
pensated by second VH-DHJH rear-
rangement attempts on the alternative
allele (Sonoda et al., 1997; ten Boekel
et al., 1998). In-frame VHDHJH rearran-
gements lead to the expression of
functional mH polypeptides and their
association with the surrogate light
chain, a light-chain-like chaperone
complex comprising the Vpre-B and
l5 polypeptides (Karasuyama et al.,
1990, 1993). This point in B-lineage
development defines the pre-B cell
stage (Goldsby et al., 2003) and the
mH and surrogate light chain polypep-
tides associate with the Iga/Igb hetero-
dimer to form a pre-BCR (Karasuyama
et al., 1996) that provides constitutive
survival and proliferation signals. Fol-
lowing the assembly of pre-BCR, pre-B
cells undergo several rounds of cell
division and a coincident reduction in
RAG1/2 expression (Hardy et al., 1991;
Lin and Desiderio, 1993; Li et al., 1996)
as large pre-B cells; after their arrest in
the G1 phase of the cell cycle (Li et al.,
1993) the cells are known as small pre-B
cells. RAG1/2 expression becomes ele-
vated in small pre-B cells to drive Vk-to-
Jk light (L)-chain rearrangements (Reth
et al., 1987; Schlissel and Baltimore,
1989). L-chain expression leads to the
assembly of mature BCR by the replace-
ment of surrogate light chain with Igk or
Igl polypeptide (Alt et al., 1987;
Rajewsky, 1996). These immature B
cells are the first in the B lineage to
express the BCR on their surfaces and to
become capable of recognizing exogen-
ous antigens (Hardy et al., 1991; Hardy
and Hayakawa, 2001).
The generation of functional antigen
receptors—the BCR—by genetic re-
arrangement and the combinatorial as-
sociation of gene segments ensures a
diverse repertoire of antibody and B-cell
specificities but also the generation of
self-reactive clones (Nemazee and Wei-
gert, 2000). Thus, the newly generated
pool of immature B cells is purged of
self-reactivity by at least three mechan-
isms of immunological tolerance: apop-
totic deletion, inactivation by anergy,
and receptor editing, the replacement of
autoreactive BCR by secondary V(D)J
rearrangement (Nemazee and Weigert,
2000). B cells that survive this negative
selection may enter one of the mature B-
cell compartments, including the ma-
ture follicular pool that recirculates
through peripheral tissues (Gray et al.,
1982) and the fixed splenic marginal-
zone compartment (Martin and Kear-
ney, 2002; Lopes-Carvalho and Kear-
ney, 2004; Berland et al., 2006). These
mature compartments respond to anti-
gens by distinct pathways of differentia-
tion to produce specific antibody and/or
establish pools of high affinity memory
B cells that persist for long periods of
time. The memory pathway appears to
be largely reserved for the mature
follicular compartment whereas margin-
al-zone B cells provide rapid but
transient antibody responses (Oliver
et al., 1999).
EARLY B-CELL DEVELOPMENT
In adult mice and humans, BM is the
primary site of B lymphopoiesis and the
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screening of newly formed B lympho-
cytes for self-reactivity. Many of the
characteristic events of B-cell develop-
ment, including the rearrangement of
the Igh and Igk/l gene loci, correlate
with expression of surface markers,
allowing the definition of specific
stages in B-cell development by multi-
parameter flow cytometry (Osmond
et al., 1998). That several phenotypic
definitions have been used by different
laboratories to describe B-cell develop-
ment has led to slightly different
models/nomenclature for B lymphopoi-
esis (Osmond et al., 1998). To avoid
confusion, and for the sake of simpli-
city, in this review we shall focus on
the molecular events that define B-cell
development.
B cells derive from multipotent, self-
renewing hematopoietic stem cells
(HSC) and transit through a series of
maturational steps and developmental
checkpoints in the BM (Kondo et al.,
2003; Hardy et al., 2007). The initial
developmental checkpoint that defines
the B lineage is the lymphoid/myeloid
branch point which is thought to occur
at or after HSC differentiation into
nonrenewing multipotent progenitors
that express the adhesion molecule
VCAM-1 (Figure 1) (Kondo et al.,
2003). Functional analyses suggest that
multipotent progenitors first lose the
potential for megakaryocyte/erythroid
differentiation, followed by a dimin-
ished capacity to generate granulocytes
and macrophages, and the eventual
commitment to the lymphoid lineages
(Adolfsson et al., 2005; Lai and Kondo,
2006). B lineage specification begins as
early as the VCAM-1 multipotent
progenitor stage of development, also
known as the early lymphoid progeni-
tor, where cells express B-cell-specific
transcription factors together with other
lineage-specific molecules (Igarashi
et al., 2002; Lai et al., 2005). The more
differentiated, common lymphoid pro-
genitors (CLPs) give rise to pre-pro-B
cells (also known as CLP-2) and com-
pletely lose T- and NK-cell potential
upon reaching the pro-B stage (Figure 1;
Tudor et al., 2000).
Extracellular factors are necessary
for the expression of B-cell-specific
transcription factors, including EBF
(early B-cell factor), LRF (liver regen-
eration factor), and Pax5 (paired box).
In mice, IL-7 receptor (IL-7Ra) signaling
is necessary for the expression of EBF,
at least at the transition of CLP to pre-
pro-B cells/CLP-2, as B-cell develop-
ment is blocked at the pre-pro-B stage
in IL-7- and IL-7Ra-deficient mice as a
consequence of low EBF expression
(Dias et al., 2005; Kikuchi et al., 2005).
Similarly, lack of the transcriptional
repressor LRF (also known as Pokemon)
arrests B-cell development at the pre-
pro-B/CLP-2 stage and results in extra-
thymic T-cell development in BM
(Maeda et al., 2007), presumably as
the result of altered Notch signaling
(Pui et al., 1999; Radtke et al., 1999).
Another B-lineage transcription factor,
Pax5, is also expressed in CLP, even
though one of its targets, the B-lineage
signal transducer, CD19, is not (Hsu
et al., 2006). Presumably, Pax5 levels
are insufficient in CLP to induce this
critical target and establish B-cell com-
mitment (Hsu et al., 2006). B-cell-
specific transcription factors form tran-
scriptional networks along with more
generally expressed transcription fac-
tors including PU.1 and E2A (Nutt and
Kee, 2007). In pro-B cells, Pax5 and
Stat5 interact and critically regulate the
accessibility of the Igh gene loci to the
RAG1/2 recombinase and thereby con-
trol the VH-to-DHJH rearrangements
necessary for the production of mH
polypeptides (Fuxa et al., 2004; Berto-
lino et al., 2005). Pax5 and E2A are
also important in regulating the expres-
sion of the surrogate light chain poly-
peptides, Vpre-B and l5 (Melchers,
2005); in addition, E2A plays a crucial
role in the regulation of Igk rearrange-
ment (Lazorchak et al., 2006) and
consequently, the generation of imma-
ture B cells that express mature BCR
capable of interacting with exogenous
and self-antigens.
Roughly 90% of the cells that
commit to the B lineage do not reach
the immature B-cell stage (Rolink et al.,
1998). Many, perhaps as many as 75%,
of developing B cells express BCR that
recognize self-antigens (Wardemann
et al., 2003). Immature B cells that
encounter their antigen ligands in the
BM undergo apoptosis (Nemazee and
Buerki, 1989), or are rendered non-
functional by the process known as
anergy (Goodnow et al., 1988), or
HSC VCAM
+
MPP
VCAM–
MPP CLP pre-pro-B pro-B pre-BI
Large
pre-BII Imm B
Small
pre-BII
Self-renewal or
maturation
Lymphoid or
myeloid T or B
B-lineage
commitment
Maturation or
neglect
MPP ELP Hardy’s Fr. A
CLP2
Fr. B
B
Fr. C Fr. C′ Fr. D Pr. E
T, B, MegE, GM T, B, GM T, B
IgH GL GL ~ D to J V to DJ VDJ
IgL GL V to J VJ
Figure 1. B cell development in bone marrow. The step-wise differentiation of hematopoietic stem cells (HSC) into immature B cells in the bone marrow is
depicted. Hematopoietic lineage potential gradually decreases as HSC mature through multipotent progenitors (MPP) and early lymphoid progenitors (ELP) to
common lymphoid progenitors (CLP). The differentiation potential of each progenitor type to give rise to T cells (T), B cells (B), megakaryocyte/erythroid cells
(MegE), and granulocytes/macrophages (GM) is indicated. Cells that commit to the B-lineage progress through a series of additional developmental stages
defined by the rearrangement of immunoglobulin genes. The stages at which the immunoglobulin heavy chain genes (IgH) and light chain genes (IgL) rearrange
are shown (GL, germline configuration). For reference, Hardy’s nomenclature for murine B-cell development is shown (Hardy et al., 1991).
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reactivate Ig gene rearrangement to
replace the self-reactive BCR (Gay
et al., 1993; Radic et al., 1993; Tiegs
et al., 1993). This last tolerance me-
chanism, receptor editing, is unusual in
that it operates on the autoreactive
receptor rather than the autoreactive
cell (Nemazee and Weigert, 2000).
Once past this initial tolerance check-
point, the residual immature B-cells
begin a series of maturation steps as
they emigrate from the BM to the
spleen or other peripheral lymphoid
tissues where they complete their
development.
PERIPHERAL B-CELL DEVELOPMENT
The final stages of B-cell development
take place in the spleen where transi-
tional B cells (Carsetti et al., 1995),
essentially intermediate forms between
the immature and mature phenotypes,
undergo selection into the peripheral
B-cell compartments (Loder et al.,
1999). Type 1 transitional (T1) B cells
continue to mature through the Type 2
transitional (T2) B-cell stage, which in
turn completes B-cell development/
maturation as mature follicular or
marginal-zone B cells. Tolerance con-
tinues to operate during the T1 and T2
stages of B-cell development, as the
frequency of self-reactive clones con-
tinues to decrease through the imma-
ture, T1, and T2 stages of B-cell
development (Wardemann et al.,
2003). However, unlike immature B
cells, T1 B cells do not appear to be
able to undergo receptor editing on
exposure to self-antigen ligands (Wang
et al., 2007). Instead, T1 cells undergo
apoptosis following BCR ligation
whereas BCR ligation on T2 B cells
induces proliferation and differentia-
tion to antibody secretion similar to
mature B cells (Petro et al., 2002).
Though the mechanism is still unclear,
studies of the frequencies of VH genes
in immature and mature B cell popula-
tions have uncovered biases in VH gene
usage, suggesting that positive selec-
tion also occurs in the transitional
stages of B-cell development (Gu
et al., 1991; Levine et al., 2000).
In addition to tonic BCR signaling,
extracellular factors are required for
transitional B cells to complete their
development. B-cell activating factor of
the TNF family (BAFF) is an important
regulator of transitional B-cell matura-
tion, and controls the T1-T2 transi-
tion. Mice deficient of BAFF have
severely reduced numbers of B cells
beyond the T1 stage of development
but have normal numbers of develop-
ing B cells in BM (Schiemann et al.,
2001; Gorelik et al., 2003; Shulga-
Morskaya et al., 2004). Three receptors
for BAFF have been identified, trans-
membrane activator and calcium-mod-
ulator and cyclophilin-ligand interactor
(TACI), B-cell maturation antigen
(BCMA), and BAFF receptor (BAFF-R;
Mackay and Browning, 2002). How-
ever, BAFF-R is the principal receptor
for controlling peripheral B-cell devel-
opment, as mice deficient in this
receptor exhibit a phenotype compar-
able to BAFF-deficient mice (Sasaki
et al., 2004). BAFF-R signaling activates
several transcription factors, including
NF-kB (Kanakaraj et al., 2001), as well
as expression of antiapopototic genes,
including Bcl-2, Bcl-xL, and Mcl-1 (Do
et al., 2000; Hsu et al., 2002; Hatada
et al., 2003; Woodland et al., 2008).
Signaling through BAFF-R also upregu-
lates the expression of CD21 and
CD23, B-cell associated receptors (for
complement and IgE, respectively) that
distinguish T1 B cells from more
mature T2 and mature B cells (Gorelik
et al., 2004).
A recent study identified a subset of
T2 B cells that are highly sensitive to
proliferative signals through BAFF-R,
suggesting that BAFF targets this popu-
lation as part of the homeostatic
regulation of peripheral B-cell devel-
opment (Meyer-Bahlburg et al., 2008).
Further evidence for BAFF as a homeo-
static regulator of peripheral B lympho-
poiesis is based on observations that
patients exhibit significant increases in
serum BAFF concentrations during B-
cell depletion therapy (Cambridge
et al., 2006; Pers et al., 2007), suggest-
ing that BAFF concentrations mediate
the size of the peripheral B-cell pool.
Interestingly, transgenic mice that ex-
press high levels of BAFF exhibit large
increases in the numbers of T2 and
mature B cells, and typically show
evidence of systemic autoimmune dis-
ease (Mackay et al., 1999; Batten et al.,
2000; Khare et al., 2000). Presumably,
BAFF overexpression allows for the
survival of T1 B cells that would
normally be purged by apoptosis (Thien
et al., 2004). Consistent with this
hypothesis, transgenic B cells bearing
self-reactive receptors are more depen-
dent on BAFF for survival than are
alloreactive B cells (Lesley et al., 2004).
Elevated serum BAFF has also been
associated with several autoimmune
diseases, including lupus, rheumatoid
arthritis, and Sjogren’s syndrome
(Cheema et al., 2001; Zhang et al.,
2001; Groom et al., 2002; Jonsson
et al., 2005; Becker-Merok et al.,
2006), garnering much attention for
BAFF as a potential therapeutic target.
Though BAFF production is typically
attributed to myeloid cells, experiments
with reciprocal BM chimeras demon-
strated that BAFF production by radia-
tion-resistant (presumably nonhemato-
poietic) cells is necessary for peripheral
B-cell development and sufficient for
humoral immune responses (Gorelik
et al., 2003). However, BAFF-deficient
mice reconstituted with BAFF-sufficient
BM mount antibody responses to im-
munization with T-cell dependent anti-
gens, indicating that hematopoietic cell-
derived BAFF contributes significantly to
B-cell maintenance and their differentia-
tion to antibody-secreting cells. Hema-
topoietic sources of BAFF include
dendritic cells (Schneider et al., 1999),
macrophages (Craxton et al., 2003),
neutrophils (Scapini et al., 2003), T cells
(Yoshimoto et al., 2006), and even B
cells themselves (Chu et al., 2007;
Daridon et al., 2007).
BAFF is required for normal periph-
eral B-cell development, but is it
necessary for mature B cells during an
immune response? A role for BAFF in
the maintenance of germinal centers
has been proposed based on the
observation that BAFF-deficient and
BAFF-R-deficient mice have attenuated
germinal center responses (Rahman
et al., 2003; Vora et al., 2003). How-
ever, a recent study found that freshly
isolated germinal center B cells have
no detectable BAFF bound to their
surface receptors, though they express
receptors capable of binding exogen-
ous BAFF (Darce et al., 2007). Follicu-
lar B cells, on the other hand, have
BAFF bound to their surface receptors.
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Together these findings suggest that the
germinal center is a BAFF-poor envir-
onment, consistent with the concept
that the survival of germinal center B
cells is determined by competition for
antigen (Kelsoe, 1996). It seems possi-
ble, therefore, that attenuated germinal
center responses in BAFF-deficient
mice may be explained better by the
indirect effects of BAFF on B-cell
development. We note that the few B
cells that reach maturity in BAFF-
deficient mice do not express CD21, a
receptor for the complement activation
products C3d and C3b (Carroll, 2004).
The binding of CD21 to C3-decorated
antigen strongly amplifies BCR signal-
ing (Fearon and Carroll, 2000) and
mice deficient in CD21 exhibit de-
creased antibody responses to T-depen-
dent antigens (Ahearn et al., 1996;
Molina et al., 1996), at least in part
due to the inability of CD21-deficient B
cells to persist in germinal centers
(Fischer et al., 1998).
Although a direct role for BAFF in
germinal centers can be debated, other
B-cell compartments may rely on BAFF
to generate effective humoral re-
sponses. BAFF has been implicated in
T-independent antibody responses to
infection and has been shown to
promote class switching independently
of T-cell derived CD40 ligand (Litinskiy
et al., 2002; Castigli et al., 2005),
observations that suggest a direct link
between B cells and innate immune
cells in T-independent humoral re-
sponses. Finally, BAFF production by
blood dendritic cells also appears to be
required for the differentiation of mar-
ginal-zone B cells into plasmacytes
secreting low-affinity antibody during
the early humoral response to bacterial
infections (Balazs et al., 2002).
INFLAMMATION AND
B LYMPHOPOIESIS
Although infection and inflammation
have long been known to affect leuko-
cyte production (Apperley et al., 1989;
Young et al., 1989; Nagaoka et al.,
2000), it has only been in recent years
that the molecular and cellular details
of inflammatory hematopoiesis have
been explored (Figure 2). Several re-
cent studies demonstrated that inflam-
mation alters hematopoietic output of
BM by favoring myelopoiesis, espe-
cially granulopoiesis, over lymphopoi-
esis (Nagaoka et al., 2000; Ueda et al.,
2004, 2005; Nagai et al., 2006). Our
current understanding of how inflam-
mation affects B lymphopoiesis is
based on three mechanisms: (1) diver-
sion of lymphoid progenitors from the
B lineage; (2) induction of apoptosis in
developing B cells; and (3) mobiliza-
tion of developing B cells to the
periphery.
Remarkably, microbial products can
have direct effects on the differentiation
of hematopoietic progenitors. Nagai
et al. (2006) have demonstrated that
hematopoietic progenitors express at
least some Toll-like receptors (TLR) and
that TLR ligation induces their differ-
entiation into innate immune cells. CLP
incubated with TLR ligands differenti-
ate into dendritic cells in vitro. Redir-
ected differentiation of CLP into
dendritic cells as a result of TLR ligation
could reduce the B-cell progenitor
pool, limiting B lymphopoiesis during
infection; whether this potential reduc-
tion is manifest during infections and/or
chronic inflammation is unknown but
may represent a significant aspect of
clinical management. Hopefully, we
will soon understand how signaling
through TLR overrides the fate deci-
sions that are already established in
CLP, such as the expression of Pax5
and the RAG1/2 recombinase.
Hematopoiesis is also affected by
inflammatory cytokines. TNFa, perhaps
the premiere proinflammatory cytokine
(Beutler and Cerami, 1989), is known
to play a major role in modulating B
lymphopoiesis. For example, the BM of
mice infected with influenza have
significantly lower numbers of devel-
oping B cells due to the antiprolifera-
tive effects of TNFa and lymphotoxin
(LTa; Sedger et al., 2002). However,
this study did not demonstrate whether
the proliferative suppression by TNFa
and LTa was direct or acted indirectly
by altering the BM environment.
More recently, TNFa has been
shown to affect B lymphopoiesis by
regulating the expression of chemo-
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Figure 2. Inflammation induces extramedullary B lymphopoiesis. A simplified schematic of
hematopoiesis during normal and inflamed conditions is depicted, with B-cell development progressing
from hematopoietic stem cells (HSC) through common lymphoid progenitors (CLP), pro-B cells (pro-B),
pre-B cells (pre-B), immature B cells (imm B), transitional 1 B cells (T1), transitional 2 B cells (T2), and
mature B cells (Mat B). From HSC, granulocyte differentiation occurs through common myeloid
progenitors (CMP), myeloblasts (MB), promyelocytes (PM), and polymorphonuclear neutrophils (PMN).
Toll-like receptor (TLR) signals induce HSC to develop into myeloid cells and CLP to develop into
dendritic cells (DC). TNFa reduces CXCL12 and stem cell factor (SCF) expression by bone marrow
stromal cells, resulting in the mobilization of developing B-lineage cells to peripheral lymphoid tissues
such as the spleen, where they continue to mature.
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kines and growth factors in BM. The
CXCL12/CXCR4 axis is crucial to he-
matopoiesis (Nagasawa et al., 1996;
Nagasawa, 2006) and is a target of
inflammatory signals (Fedyk et al.,
2001). The importance of this chemo-
kine in B lymphopoiesis is evident in
CXCL12-deficient mice, which have
severely reduced B-cell numbers (Na-
gasawa et al., 1996). Similarly, block-
ing CXCR4 with antagonists in vivo
mobilizes B cells from the BM into the
circulation (Martin et al., 2003). On a
finer scale, CXCL12 gradients in the
BM may guide developing B cells to
different microenvironments; Martin
and colleagues proposed that CXCL12
is a necessary component of the step-
wise progression of developing B cells
through specialized BM ‘‘niches’’
(Tokoyoda et al., 2004). They observed
that early B lineage cells (pre-pro-B/
CLP-2 cells) associate with CXCL12-
expressing reticular cells whereas B-
lineage cells in the subsequent, more
mature developmental stage (that is,
pro-B cells) associate with reticular
cells that express IL-7 but not CXCL12.
Mice immunized with sterile adju-
vants such as alum also exhibit sig-
nificant decreases in the numbers of
developing B cells in the BM. This loss
of developing B cells correlates with a
reduction in BM CXCL12 (Ueda et al.,
2004); indeed adjuvant-induced reduc-
tions in CXCL12 expression and the
concomitant mobilization of B cells
from BM to blood circulation are
attenuated in TNFa-deficient mice,
demonstrating that TNFa can modulate
B lymphopoiesis by reducing the ability
of the BM to retain developing B cells.
This premature emigration may reflect
the physiologic process for removing
transitional B cells into the periphery
(Fedyk et al., 1999) but results in a
transient loss of central B lymphopoi-
esis (Ueda et al., 2004, 2005).
Inflammation also affects the expres-
sion of stem cell factor (SCF) in BM.
The receptor for SCF, c-Kit, is expressed
by HSC (Ikuta et al., 1991; Ogawa
et al., 1991), myeloid progenitors
(Akashi et al., 2000), CLPs (Kondo
et al., 1997), and early B-cell progeni-
tors (Hunte et al., 1998). Mice with
inactive c-Kit exhibit age-dependent
blockades in B-cell development
(Waskow et al., 2002), indicating that
B lymphopoiesis in mice older than 10
days requires SCF. Adjuvant immuni-
zation decreases SCF expression in BM,
which, like CXCL12 expression, coin-
cides with the mobilization of devel-
oping B cells to the circulation (Ueda
et al., 2005). However, the inflamma-
tory mediator(s) that alters SCF produc-
tion in BM is not known.
The reduction in B-cell production
during an inflammatory response is
accompanied by increased production
of neutrophils, a process referred to as
‘‘emergency granulopoiesis’’ (Basu
et al., 2000; Hirai et al., 2006). The
reciprocal production of B cells and
granulocytes suggests that the progeni-
tors of each compartment utilize
a common developmental niche
(Figure 2). This hypothesis is supported
by the observation that developing B
cells and granulocytes colocalize be-
neath BM stromal cells in vitro to form
mixed ‘‘cobblestone clusters’’ (Ueda
et al., 2005). Interestingly, the intrave-
nous administration of recombinant
TNFa reduces CXCL12 in BM and
mobilizes developing B cells to the
periphery, but has only a modest effect
on granulopoiesis. On the other hand,
administration of IL-1 to mice, a proin-
flammatory cytokine that has been
linked to granulopoiesis (Moore and
Warren, 1987; Stork et al., 1988;
Hestdal et al., 1992; Ueda et al.,
2005), modestly increases BM neutro-
phil numbers but does not affect B
cells. However, co-administration of
TNFa and IL-1b recapitulates all of
the effects of adjuvant-induced inflam-
mation, mobilizing BM B cells to the
periphery and significantly enhancing
granulopoiesis, suggesting that these
two proinflammatory cytokines syner-
gize to redirect hematopoiesis in favor
of granulopoiesis (Ueda et al., 2005).
Inflammation-induced reductions in
BM B cells are accompanied by in-
creases in the number of developing B
cells in the spleen, indicating that
inflammation mobilizes developing B
cells from BM to the periphery (Nagaoka
et al., 2000; Ueda et al., 2004, 2005).
The fact that inflammation mobilizes
developing B cells instead of inducing
apoptosis leads to an important ques-
tion: do developing B cells that have
mobilized to the periphery continue
their development outside of BM? The
primary implication of extramedullary
lymphopoiesis is that B cells could
develop in a ‘‘selection-light’’ environ-
ment (Sandel et al., 2001). Develop-
ment in such an environment might
allow for the survival of self-reactive B
cells that would normally be deleted in
the BM, thereby raising the potential for
autoimmune pathology. This hypoth-
esis provides a potential mechanism to
explain the strong linkage between
inflammation and the induction of
systemic autoimmune disease.
On the other hand, the possibility of
immature B cells playing a role in
immune responses to pathogens cannot
be excluded. Immature B cells are
prominent in the spleens of adjuvant-
immunized mice, placing them in an
ideal position to interact with blood-
borne antigens. Support for this model
was provided in a recent report that
focused on antibody production by
immature/T1 B cells (Ueda et al.,
2007). In this study, the authors ob-
served that the number of splenic T1 B
cells significantly increased during in-
flammation as a result of extramedul-
lary lymphopoiesis. Though signaling
through BCR alone induces apoptosis
in T1 B cells (Petro et al., 2002),
lipopolysaccharide stimulation in vitro
induces proliferation and secretion of
class-switched antibody, an effect sig-
nificantly augmented by the inclusion
of BAFF. This observation indicates that
T1 B cells are competent to respond to
positive BCR signals and participate in
T-independent humoral responses. The
production of class-switched antibody
requires the activity of activation-
induced cytosine deaminase (AID).
Surprisingly enough, T1 B cells, but
not T2 B cells, have been found to
express functional levels of AID as part
of their developmental program, rather
than in response to TLR ligation or T-
cell help (Ueda et al., 2007). In
addition, T1 B cells express low but
significant amounts of Blimp-1 (B-
lymphocyte maturation promoting), a
transcription factor required for differ-
entiation into antibody secreting cell
(Turner et al., 1994; Angelin-Duclos
et al., 2000). Together, these observa-
tions suggest that T1 B cells, like
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marginal-zone B cells, may be poised
to respond rapidly to antigens as part of
the ‘‘innate’’ humoral response. This
notion is supported by the recent
observation that human transitional B
cells differentiate into plasmacytes
upon encounter with TLR ligands (Ca-
polunghi et al., 2008).
What is the physiologic role of
antigen-responsive T1 B cells? As T1 B
cells have not completed developmen-
tal selection, they are enriched for self-
reactive clones compared to mature
follicular B cells (Wardemann et al.,
2003). Normally, the production of
low-affinity, polyreactive antibody dur-
ing the early immune responses is
attributed to B-1 and marginal-zone B
cells (Martin et al., 2001) but the ability
of T1 B cells to respond quickly to
antigen (Ueda et al., 2007) suggests
that these developmentally immature
cells may also contribute to early
humoral defense.
The observation that lipopoly-
saccharide-stimulated T1 B cells are
dependent on BAFF for survival (Ueda
et al., 2007) raises the possibility that
BAFF serves as the limiting factor in the
recruitment of T1 B cells into immune
responses. In this model, the amount of
BAFF available in normal, uninfected
individuals would be sufficient for B-
cell development, maturation, and
homeostasis, but not high enough to
allow the survival of T1 B cells that
encounter self- or exogenous antigens.
Conversely, increased BAFF production
during infection would promote the
survival of T1 cells that encounter
antigen, allowing their participation in
immune responses. Indeed, the obser-
vation that dendritic cells upregulate
BAFF production in response to inflam-
matory cytokines suggests that modu-
lated BAFF production during infection
may represent a physiological and
protective response to abet humoral
immunity (Litinskiy et al., 2002).
CHRONIC INFLAMMATION AND B
LYMPHOPOIESIS
If acute inflammation, even the modest
inflammation that results from immu-
nization with adjuvant, affects central
hematopoiesis, what are the effects of
persistent inflammation? Generally, in-
flammation is regarded as a beneficial,
self-limiting, healing process, allowing
for the clearance of the initiating
stimuli via localized recruitment of
immune effector cells. However, when
the inflammatory stimulus persists, the
resulting chronic inflammation can be
protective or pathogenic depending on
the circumstances. For example, gran-
ulomas can wall off persistent inflam-
matory agents when the normal
mechanisms of antigen clearance fail
or are otherwise insufficient (Chatto-
padhyay, 1994).
We and many others have used
pristane (2,6,10,14-tetramethylpenta-
decane), a natural, saturated 19-C
alkane, to induce chronic peritoneal
inflammation (Richards et al., 1999;
Potter, 2003). When injected into the
peritoneal cavity, pristane is either
phagocytosed by macrophages or sur-
rounded by infiltrating leukocytes to
form oil–cell complexes. These com-
plexes adhere to peritoneal surfaces
and preferentially to the mesenteric
membranes (Potter and Maccardle,
1964). With time, the infiltrating leuko-
cyte complexes expand to form struc-
tures known as oil granulomas.
Chronic inflammation induces ter-
tiary lymphoid tissues via the same
cellular and molecular signals that
direct the organization and formation
of secondary lymphoid tissues (Drayton
et al., 2006). Mice deficient of TNFa
(TNFa/), LTa (LTa/), or mature B
cells (mMT) exhibit impaired abilities to
form normal secondary lymphoid tis-
sues including lymph nodes and
Peyer’s patches (De Togni et al.,
1994; Pasparakis et al., 1996; Fu
et al., 1998; Gonzalez et al., 1998).
The generation of organized oil granu-
lomas under conditions of chronic
inflammation led us to question
whether these granulomas might be
considered a sort of tertiary lymphoid
tissue (Potter and Maccardle, 1964;
Nacionales et al., 2006). If so, muta-
tions that affect the development of
secondary lymphoid tissues might also
be expected to interfere with oil gran-
uloma development and/or organiza-
tion. To investigate this potential
relationship, we injected C57BL/6 mice
that were genetically deficient of genes
(TNFa (Pasparakis et al., 1996), LTa
(De Togni et al., 1994), mMT (Kitamura
et al., 1991), and LAT (Zhang et al.,
1999)) known to be important in the
development and organization of sec-
ondary lymphoid tissues. Remarkably,
the mutation with the strongest effect
on oil granuloma formation was mMT,
an IgCm mutation that prevents com-
plete B-cell development (Kitamura
et al., 1991). The mMT mutation is
effective in interfering with the devel-
opment of secondary lymphoid tissues,
but these tissues normally contain large
numbers of B cells (Ngo et al., 2001;
Tumanov et al., 2004). We note that
the mMT mutation also blocks the
formation of oil granulomas even
though very few B cells are present in
the granuloma structure (manuscript in
preparation). TNFa/ mice exhibit
modestly impaired granuloma forma-
tion after pristane whereas oil granulo-
ma development in LTa-deficient mice
is comparable to normal controls
(manuscript in preparation). From these
observations, we conclude that pris-
tane-induced granulomas likely repre-
sent an inflammatory tissue that is
organized, at least in part, by the
genetic pathways that also organize
secondary and tertiary lymphoid tis-
sues. B cells, though rare in the oil
granulomas of C57BL/6 mice, appear
to exert a powerful effect on the
development of these tissues.
Chronic inflammation may also
contribute to the development of B-cell
tumors. Pristane-induced oil granulo-
mas contain macrophages and fibro-
blasts that secrete IL-6 (Fagarasan et al.,
2000; Potter, 2003), an inflammatory
cytokine that promotes the differentia-
tion of B cells into plasmacytes (Roldan
and Brieva, 1991). Mice that over-
express IL-6 develop spontaneous mye-
lomas and lymphomas at much higher
rates than control mice (Kovalchuk
et al., 2002). Plasmacytes bearing the
chromosomal translocations t(12;15) or
t(6;15) proliferate and survive within
the IL-6-rich environment of pristane-
induced oil granulomas, resulting in
the development of plasmacyte tumors
called plasmacytomas or myelomas
(Fagarasan et al., 2000; Potter, 2003).
Thus, granulomatous tissues associated
with chronic inflammation promote
specific B-cell tumors by providing an
environment where neoplastic B cells
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or plasmacytes escape normal regula-
tory cues.
Interestingly, the development of
pristane-induced plasmacytomas is
strain dependent; BALB/c mice are
susceptible whereas C57BL/6 mice are
resistant, indicating that the genetic
differences between the strains affect
both granuloma development and pre-
disposition for plasmacytomas. Indeed,
oil granulomas in C57BL/6 and BALB/c
mice differ in their anatomical location
on the mesentery; in C57BL/6 mice,
pristane elicits oil granulomas at the
gut/mesentery boundary whereas in
BALB/c mice granulomas are centripe-
tally distributed on the mesentery
(Potter and Maccardle, 1964 and
manuscript in preparation). The identi-
fication of genes that regulate oil
granuloma formation is required to
understand better the differential sus-
ceptibilities to pristane-induced plasma-
cytomas. At least two genes that confer
resistance to plasmacytomas elicited by
pristane have been identified (Potter
et al., 1994), but their roles in oil
granuloma development are unknown.
Chronic inflammation is also asso-
ciated with the induction or exacerba-
tion of autoimmunity. Pristane-induced
autoimmunity is observed in many
strains of mice (Satoh et al., 2000,
2003; Mizutani et al., 2005) and has
been linked to the induction of apop-
tosis by peritoneal cells, which pro-
vides the autoantigen substrate
necessary to break tolerance (Potter
and Maccardle, 1964; Calvani et al.,
2005; Kirou et al., 2005; Zhuang et al.,
2005). Sequestration of pristane by
granuloma formation may act to inhibit
autoimmunity; C57BL/6 mice wall off
injected pristane much more efficiently
than do BALB/c mice and C57BL/6
mice are less prone to develop severe
autoimmune disease in response to
pristane than are BALB/c mice (Potter
and Maccardle, 1964; Wooley et al.,
1989; Nacionales et al., 2006).
CONCLUSIONS
There is much more to hematopoiesis
and B-cell development than the nor-
mal, steady-state hematopoietic path-
ways that have been described in naive
mice and humans. Inflammation redir-
ects central hematopoiesis by altering
the BM environment to favor myelo-
poiesis and by mobilizing developing B
cells to the blood and peripheral
lymphoid sites, where exposure to
antigens and inflammatory agents are
common. The utility, consequences,
and potential dangers of extramedul-
lary B lymphopoiesis are not yet known
but deserve additional study and con-
sideration, especially in the light of the
persistent inflammation associated with
chronic infection and autoimmunity. In
the periphery, B-cell tolerance may be
less efficient and the capacity of
activation-induced cytosine deami-
nase-positive T1 B cells to respond to
antigenic stimuli suggests a pathway for
generating and expanding clones of B
cells reactive with self-antigens. A
particularly attractive test of this
hypothesis may be found in the epitope
spreading associated with the desmo-
glein antibodies responsible for pem-
phigoid disease (Ishii et al., 1997;
Amagai et al., 1999; Miyagawa et al.,
1999; Futei et al., 2000; Tsunoda et al.,
2002).
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